ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Ohr Pharmaceutical Inc (OHRP) Report Updated: Nov 17, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Ohr Pharmaceutical Inc (OHRP)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Biotechnology
Competitors: ENTA, GILD, FOLD, MDXG

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: C down no change
Last Week: C same downgrade
Two Weeks Ago: B up no change
service keys

Ohr Pharmaceutical Inc© quotemedia

Company Profile

OHR Pharmaceutical, Inc. operates as a biotechnology company. The company’s product line includes Squalamine, an anti-angiogenic small molecule with a novel intracellular mechanism of action that inhibits vascular endothelial, platelet derived and basic fibroblast growth factors for the treatment of the wet form of age-related macular degeneration. It also offers OHR/AVR 118, which is in Phase II clinical trial for the treatment of cancer cachexia, a multi-symptom wasting disorder characterized by weight loss, muscle atrophy, fatigue, weakness, and significant loss of appetite. The company is headquartered in New York, New York.

Recent News: Ohr Pharmaceutical Inc